Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy GHRS?
Source: Benzinga
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GHRS
Wall Street analysts forecast GHRS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.850
Low
19.00
Averages
28.60
High
35.00
Current: 14.850
Low
19.00
Averages
28.60
High
35.00
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Helus Pharma Advances Mental Health Drug Development
- Clinical Trial Progress: Helus Pharma's SPL026 showed significant efficacy in a randomized Phase 2 trial for major depressive disorder, with a mean MADRS score reduction of 7.35 in the 21.5 mg dose group among 34 participants, indicating its potential in the mental health sector.
- New Drug Development: The company is advancing HLP003 through Phase 3 trials, which has received FDA Breakthrough Therapy Designation, with preliminary data showing a 100% response rate and 71% remission rate at 12 months, highlighting its importance in treating major depressive disorder.
- Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash reserves, providing strong financial backing for the continued advancement of its multi-asset clinical pipeline, ensuring sustainability for future R&D efforts.
- Market Outlook: As regulatory approvals for mental health drugs draw closer, Helus Pharma and its peers are reshaping the market perception of psychedelic drugs, which is expected to create significant commercial opportunities and enhance market share for the company.
See More
Helus Pharma Advances Psychedelic Drug Clinical Trials
- Clinical Trial Progress: Helus Pharma's SPL026 achieved a mean MADRS difference of -7.35 (p=0.023) in a randomized Phase 2 trial involving 34 participants with major depressive disorder, indicating significant efficacy and potential in the mental health sector.
- Drug Development Strategy: Helus Pharma's HLP003 has received FDA Breakthrough Therapy Designation and is advancing through two pivotal Phase 3 studies, with topline data expected in Q4 2026, showcasing the company's ongoing innovation and competitiveness in depression treatment.
- Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline, demonstrating a strong financial foundation for R&D efforts.
- Industry Recognition: A consensus statement from the U.S. National Network of Depression Centers indicates that academia is preparing to integrate psychedelics into routine clinical practice, reflecting the growing acceptance of Helus Pharma and its peers in the mental health treatment landscape.
See More
US Stocks Close Higher, S&P 500 Hits One-Week High
- Strong Market Performance: The S&P 500 index rose by 0.64%, reaching a one-week high, reflecting increased investor optimism regarding AI spending, which is driving the overall market upward.
- Energy Stocks Rally: Following President Trump's announcement of a U.S. takeover of Venezuela, energy companies saw significant gains, with Valero Energy up over 9%, indicating rising market expectations for energy resource demand.
- Increased Demand for Precious Metals: Gold prices surged over 2% and silver over 7% due to escalating geopolitical risks in South America, driving mining stocks higher and reflecting investor preference for safe-haven assets.
- Declining Bond Yields: The 10-year Treasury yield fell to 4.16%, supported by weak economic data and dovish comments from Fed officials, leading to rising bond prices and indicating changing market expectations for future interest rate policies.
See More
US Stock Indices Rise with Energy Stocks Leading Gains
- Strong Market Performance: The S&P 500 Index rose by 0.72% and the Dow Jones Industrial Average increased by 1.32%, reaching a new all-time high, reflecting strong market optimism regarding AI spending that boosted chipmakers and data storage companies.
- Energy Stock Rally: Following President Trump's announcement that the US will “run” Venezuela and require “total access” to its oil reserves, energy stocks surged, with Valero Energy leading gains at over 11%, indicating heightened market interest in energy resources.
- Rising Demand for Precious Metals: Geopolitical risks in South America have driven gold prices up by more than 3% and silver by over 7%, leading to gains in mining stocks, with Barrick Mining and Hecla Mining both rising over 4%, reflecting increased investor demand for safe-haven assets.
- Economic Data Impact: Despite the unexpected drop in the December ISM manufacturing index to 47.9, marking the steepest contraction in 14 months, dovish comments from the Philadelphia Fed President supported the stock market, suggesting continued optimism about future economic growth.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
US Stocks Rise as Energy Shares Surge on Venezuela Situation
- Market Gains: The S&P 500 Index rose by 0.54%, the Dow Jones Industrial Average increased by 0.99%, and the Nasdaq 100 Index climbed by 0.78%, reflecting strong market optimism regarding AI spending that is driving overall stock performance higher.
- Energy Stocks Surge: Following President Trump's announcement of a U.S. takeover of Venezuela, energy companies saw significant stock increases, with Valero Energy up over 9%, Halliburton and SLB rising more than 7%, indicating strong market demand for oil and gas resources.
- Rising Precious Metals Demand: Escalating geopolitical risks in South America led to gold prices increasing by over 2% and silver by more than 5%, boosting mining stocks like Barrick Mining and Newmont Mining by over 2%, reflecting investor preference for safe-haven assets.
- Fed Policy Expectations: Dovish comments from the Philadelphia Fed President supported stock market gains, with expectations of potential interest rate cuts in the future enhancing confidence in economic growth, further propelling positive stock market performance.
See More
Helus Pharma Advances Mental Health Drug Development
- Clinical Trial Progress: Helus Pharma's SPL026 showed significant efficacy in a randomized Phase 2 trial for major depressive disorder, with a mean MADRS score reduction of 7.35 in the 21.5 mg dose group among 34 participants, indicating its potential in the mental health sector.
- New Drug Development: The company is advancing HLP003 through Phase 3 trials, which has received FDA Breakthrough Therapy Designation, with preliminary data showing a 100% response rate and 71% remission rate at 12 months, highlighting its importance in treating major depressive disorder.
- Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash reserves, providing strong financial backing for the continued advancement of its multi-asset clinical pipeline, ensuring sustainability for future R&D efforts.
- Market Outlook: As regulatory approvals for mental health drugs draw closer, Helus Pharma and its peers are reshaping the market perception of psychedelic drugs, which is expected to create significant commercial opportunities and enhance market share for the company.
See More
Helus Pharma Advances Psychedelic Drug Clinical Trials
- Clinical Trial Progress: Helus Pharma's SPL026 achieved a mean MADRS difference of -7.35 (p=0.023) in a randomized Phase 2 trial involving 34 participants with major depressive disorder, indicating significant efficacy and potential in the mental health sector.
- Drug Development Strategy: Helus Pharma's HLP003 has received FDA Breakthrough Therapy Designation and is advancing through two pivotal Phase 3 studies, with topline data expected in Q4 2026, showcasing the company's ongoing innovation and competitiveness in depression treatment.
- Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline, demonstrating a strong financial foundation for R&D efforts.
- Industry Recognition: A consensus statement from the U.S. National Network of Depression Centers indicates that academia is preparing to integrate psychedelics into routine clinical practice, reflecting the growing acceptance of Helus Pharma and its peers in the mental health treatment landscape.
See More
US Stocks Close Higher, S&P 500 Hits One-Week High
- Strong Market Performance: The S&P 500 index rose by 0.64%, reaching a one-week high, reflecting increased investor optimism regarding AI spending, which is driving the overall market upward.
- Energy Stocks Rally: Following President Trump's announcement of a U.S. takeover of Venezuela, energy companies saw significant gains, with Valero Energy up over 9%, indicating rising market expectations for energy resource demand.
- Increased Demand for Precious Metals: Gold prices surged over 2% and silver over 7% due to escalating geopolitical risks in South America, driving mining stocks higher and reflecting investor preference for safe-haven assets.
- Declining Bond Yields: The 10-year Treasury yield fell to 4.16%, supported by weak economic data and dovish comments from Fed officials, leading to rising bond prices and indicating changing market expectations for future interest rate policies.
See More
US Stock Indices Rise with Energy Stocks Leading Gains
- Strong Market Performance: The S&P 500 Index rose by 0.72% and the Dow Jones Industrial Average increased by 1.32%, reaching a new all-time high, reflecting strong market optimism regarding AI spending that boosted chipmakers and data storage companies.
- Energy Stock Rally: Following President Trump's announcement that the US will “run” Venezuela and require “total access” to its oil reserves, energy stocks surged, with Valero Energy leading gains at over 11%, indicating heightened market interest in energy resources.
- Rising Demand for Precious Metals: Geopolitical risks in South America have driven gold prices up by more than 3% and silver by over 7%, leading to gains in mining stocks, with Barrick Mining and Hecla Mining both rising over 4%, reflecting increased investor demand for safe-haven assets.
- Economic Data Impact: Despite the unexpected drop in the December ISM manufacturing index to 47.9, marking the steepest contraction in 14 months, dovish comments from the Philadelphia Fed President supported the stock market, suggesting continued optimism about future economic growth.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
US Stocks Rise as Energy Shares Surge on Venezuela Situation
- Market Gains: The S&P 500 Index rose by 0.54%, the Dow Jones Industrial Average increased by 0.99%, and the Nasdaq 100 Index climbed by 0.78%, reflecting strong market optimism regarding AI spending that is driving overall stock performance higher.
- Energy Stocks Surge: Following President Trump's announcement of a U.S. takeover of Venezuela, energy companies saw significant stock increases, with Valero Energy up over 9%, Halliburton and SLB rising more than 7%, indicating strong market demand for oil and gas resources.
- Rising Precious Metals Demand: Escalating geopolitical risks in South America led to gold prices increasing by over 2% and silver by more than 5%, boosting mining stocks like Barrick Mining and Newmont Mining by over 2%, reflecting investor preference for safe-haven assets.
- Fed Policy Expectations: Dovish comments from the Philadelphia Fed President supported stock market gains, with expectations of potential interest rate cuts in the future enhancing confidence in economic growth, further propelling positive stock market performance.
See More
